Literature DB >> 20226393

Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey.

Lisa L Dwyer1, Beth Han, David A Woodwell, Elizabeth A Rechtsteiner.   

Abstract

BACKGROUND: Despite the need for and benefits of medications, polypharmacy (defined here as concurrent use of > or =9 medications) in nursing home residents is a concern. As the number of medications taken increases, so does the risk for adverse events. Monitoring polypharmacy in this population is important and can improve the quality of nursing home care.
OBJECTIVES: The aims of this article were to estimate the use of polypharmacy in residents of nursing homes in the United States, to examine the associations between select resident and facility characteristics and polypharmacy, and to determine the leading therapeutic subclasses included in the polypharmacy received by these nursing home residents.
METHODS: This was a retrospective, cross-sectional study of a nationally representative sample of US nursing home residents in 2004; the outcome was use of polypharmacy. The 2004 National Nursing Home Survey was used to collect medication data and other resident and facility information. Resident characteristics included age, sex, race, primary payment source, number of comorbidities, number of activities of daily living (ADLs) for which the resident required assistance, and length of stay (LOS) since admission. Facility characteristics included ownership and size (number of beds).
RESULTS: Of 13,507 nursing home residents who received care, 13,403 had valid responses for all 9 independent variables in the analyses. The prevalence of polypharmacy among nursing home residents in 2004 was approximately 40%. A multiple regression model controlling for resident and facility factors revealed that the odds of receiving polypharmacy were higher for residents who were female (odds ratio [OR] = 1.10; 95% CI, 1.00-1.20), were white, had Medicaid as a primary payer, had >3 comorbidities (OR = 1.57-5.18; 95% CI, 1.36-6.15), needed assistance with < or =4 ADLs, had an LOS since admission of 3 to <6 months (OR = 1.25; 95% CI, 1.04-1.50), and received care in a small, not- for-profit facility (data not shown for reference levels [OR = 1.00]). The most frequently reported medications for residents who received polypharmacy included gastrointestinal agents (laxatives, 47.5%; agents for acid/peptic disorders, 43.3%), drugs that affect the central nervous system (antidepressants, 46.3%; antipsychotics or antimanics, 25.9%), and pain relievers (nonnarcotic analgesics, 43.6%; antipyretics, 41.2%; antiarthritics, 31.2%).
CONCLUSIONS: Despite awareness of polypharmacy and its potential consequences in older patients, results of our analysis suggest that polypharmacy remains widespread in US nursing homes. Although complex medication regimens are often necessary for nursing home residents, monitoring polypharmacy and its consequences may improve the quality of nursing home care and reduce unnecessary health care spending related to adverse events. Copyright 2010 Excerpta Medica Inc. All rights reserved. Published by EM Inc USA.. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20226393     DOI: 10.1016/j.amjopharm.2010.01.001

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  52 in total

1.  A Multicomponent Intervention to Optimize Psychotropic Drug Prescription in Elderly Nursing Home Residents: An Italian Multicenter, Prospective, Pilot Study.

Authors:  Luca Pasina; Alessandra Marengoni; Simona Ghibelli; Flavio Suardi; Codjo D Djade; Alessandro Nobili; Carlotta Franchi; Gianbattista Guerrini
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

2.  Geographic region and racial variations in polypharmacy in the United States.

Authors:  Winn Cashion; William McClellan; George Howard; Abhinav Goyal; David Kleinbaum; Michael Goodman; Valerie Prince; Paul Muntner; Leslie A McClure; Ann McClellan; Suzanne Judd
Journal:  Ann Epidemiol       Date:  2015-02-07       Impact factor: 3.797

3.  Adoption of Health Information Technology Among US Nursing Facilities.

Authors:  Joshua R Vest; Hye-Young Jung; Kevin Wiley; Harold Kooreman; Lorren Pettit; Mark A Unruh
Journal:  J Am Med Dir Assoc       Date:  2018-12-20       Impact factor: 4.669

4.  Polypharmacy in Assisted Living and Impact on Clinical Outcomes.

Authors:  Barbara Resnick; Elizabeth Galik; Marie Boltz; Sarah Holmes; Steven Fix; Erin Vigne; Shijun Zhu; Regina Lewis
Journal:  Consult Pharm       Date:  2018-06-01

5.  The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review.

Authors:  Andreas Katsimpris; Jacob Linseisen; Christa Meisinger; Konstantinos Volaklis
Journal:  J Gen Intern Med       Date:  2019-06-25       Impact factor: 5.128

Review 6.  Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?

Authors:  Giuseppe Sergi; Marina De Rui; Silvia Sarti; Enzo Manzato
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

7.  Drug-related problems in institutionalized, polymedicated elderly patients: opportunities for pharmacist intervention.

Authors:  Cristina Silva; Célia Ramalho; Isabel Luz; Joaquim Monteiro; Paula Fresco
Journal:  Int J Clin Pharm       Date:  2015-01-31

8.  Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study.

Authors:  Aimee N Pickering; Megan E Hamm; Alicia Dawdani; Joseph T Hanlon; Carolyn T Thorpe; Walid F Gellad; Thomas R Radomski
Journal:  J Am Geriatr Soc       Date:  2020-02-17       Impact factor: 5.562

Review 9.  Drug-induced liver injury in the elderly.

Authors:  Jonathan G Stine; Praveen Sateesh; James H Lewis
Journal:  Curr Gastroenterol Rep       Date:  2013-01

10.  An exploration of health professionals' experiences of medicines management in elderly, hospitalised patients in Abu Dhabi.

Authors:  Saeed Al Shemeili; Susan Klein; Alison Strath; Saleh Fares; Derek Stewart
Journal:  Int J Clin Pharm       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.